Charged Alpha Stock Encyclopedia

Canadian Solar (CSIQ) Q2 2026 — Q2 2026 (three months to 30 June): net revenues $1,207.7M, -28.7% YoY and +12.0% QoQ, at the high end of the $1.0-1.2BN guide; gross margin 13.9%, inside the 13-15% guide; operating expenses $239.5M against $168.5M of gross profit, so a $71.1M operating loss. Loss attributable $76.9M, -$1.40 a share. Storage shipments 3.7 GWh, +73% YoY, ahead of a 2.8-3.2 GWh guide. On the print (27 Aug) the stock gapped -3.3%, traded to $12.92 and closed +0.79% at $13.98; the NEXT session closed -6.01% at $13.14, a settled two-day reaction of -5.26%.

The filed loss per share is -$1.40. The filed loss over the filed share count is -$1.13. The $18.2M in between is a paid-in-kind dividend on Recurrent Energy's redeemable preferred, and it appears on no line of the income statement, no line of the segment table and no line of the cash flow. It reconciles exactly to the filed half-year figure, it grew 45% in a year, and because it is paid in kind it compounds - $73M a year accruing ahead of the common, on an $892M equity.

THE CALL: HOLD (2/5, A CHEAP ASSET BASE THAT EARNS NOTHING) — base-case value ~$12.55 vs ~$13.14 today.

KEY METRICS:

- CALL: HOLD 2/5, fair value $12.55 vs the $13.14 close of 28 August (-4.5%). Bear $5.24, base $13.36, bull $21.48, weighted 30/50/20. Street: 33 analysts, consensus Buy, but ONE live target - Mizuho $18.00 on 15 June, +37% above the tape and +43% above us.

- THE LINE ON NO LINE: -$76.9M over 67,907,507 shares is -$1.13. The company filed -$1.40. The $18.2M residual is a paid-in-kind preferred dividend at Recurrent Energy ($12.6M a year ago, $16.1M last quarter). Q1+Q2 residuals reconcile to the filed half-year figure within $0.05M.

- THE SPINE: storage shipped 3.7 GWh (+73% YoY) and billed $425.9M against $432.4M a year ago - about $115/kWh from about $202/kWh, -43% per unit. Modules did the opposite: 3.1 GW (-60%) at about $0.19/W from $0.13, +44% per unit.

- THE STACK: $892M of equity against $7.1BN of debt - 11.2% of the enterprise. Book value $40.57 a share, so the tape pays 0.32x. Interest took 38% of gross profit against 9% a year ago. Q3 guide $1.3-1.5BN at 13.5-15.5% implies an operating loss at EVERY point; break-even needs a 20.2% gross margin.

What to watch: UP: storage revenue per GWh printing back above ~$130/kWh; the deferred Recurrent project sales closing in H2; gross margin recovering toward the 25.1% of one quarter ago. DOWN: another quarter at ~14% gross margin; the preferred accrual growing again off a larger base; total debt drawn past $7.1BN.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Hafnia Limited (HAFN) Q2 2026 — Q2 2026 (quarter ended 30 June 2026): net profit $277.8M, EPS $0.56 against a $0.544 bar, up from $0.15 a year ago. TCE income $372.9M from $231.2M; adjusted EBITDA $287.3M from $134.2M. Fleet TCE $44,093/day. Dividend $0.5003 a share, a 90% payout. HAFN closed at $8.47, up 2.17% on the BMO print.

Hafnia's Q2 2026 was its best quarter since 2022 - $277.8M of net profit, $0.56 a share, and a 90% payout worth $0.5003 that the CEO letter describes as an annualised yield of roughly 21%. Nine pages later, in the same filing, the coverage table says 80% of Q3 earning days are ALREADY CONTRACTED at $30,716 a day against the $44,093 that produced the record - minus 30.3%, in signed contracts rather than a forecast. And 17% of 2027 is fixed at $25,742, all of it time-charter-out, below the $26,041 and $27,347 this fleet earned in Q3 and Q4 2025 before the Gulf conflict began.

THE CALL: HOLD (3/5, THE RECORD IS REAL, THE FORWARD BOOK IS 30% LOWER) — base-case value ~$7.95 vs ~$8.47 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$7.95 vs the $8.47 close (-5.9%). Bear $6.51, base $7.65, bull $10.05. Street: Buy, $8.78 average (Danske NOK 91, Clarksons NOK 90, DNB Carnegie NOK 81, all May 2026, converted at 9.95) - we are 9% below.

- THE QUARTER: EPS $0.56 vs $0.544 bar. Net profit $277.8M incl. $39.3M vessel-sale gains and $9.9M TORM dividend income; core vessel earnings ~$228.6M ($0.46/sh). RoE 44.6% annualised. Net LTV 13.0% from 20.2%.

- THE FORWARD BOOK: Q3 80% fixed at $30,716/day (-30.3%); H2 53% at $28,917; 2027 17% at $25,742, all time-charter. NAV $8.89/sh, so HAFN trades at 0.95x a peak NAV. Break-even $16,055/day.

What to watch: UP: a November coverage table that fixes Q4 2026 and 2027 above $30,000 a day; unfixed Q3/Q4 days beating the book while LR1 pool earnings run near $74,446. DOWN: a 2027 book that extends at or below $25,742; a Q3 dividend near $0.23 as the 90% payout applies to a halved profit; a durable Hormuz reopening.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

IREN Limited (IREN) Q4 FY2026 — FY2026 (year ended 30 June 2026): revenue $707.0M, up 41.1%; AI Cloud revenue $16.4M to $128.8M; Adjusted EBITDA $269.7M to $245.7M, DOWN 8.9%; net loss $702.6M against $86.9M last year; diluted loss per share $2.22 on 316.1M shares. Reported after the close on 27 August; the stock fell 12.5% on 28 August, $40.53 to $35.45, on 88.7M shares, 2.1x the 60-day median.

Everyone is arguing about the headline loss per share. What actually matters is Note 4 of the 10-K, which the press release never mentions. IREN has $16.6bn of contracted revenue. Only $5.1bn is services backlog under ASC 606. The other $11.4bn - 69% of the book - is the contracted value of LEASE arrangements under ASC 842, and the 10-K states that no lease revenue was recognised in any period presented. IREN's flagship contract is, in accounting terms, an equipment lease. The market is paying a cloud multiple for it.

THE CALL: HOLD (3/5, THE DEMAND IS REAL, THE MULTIPLE IS NOT) — base-case value ~$30.0 vs ~$35.45 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$30.00 against the $35.45 reaction close, about 15% below. Bear $18.43, base $29.61, bull $42.47, probability-weighted 25/50/25 to $30.03. We accept the Street's own FY2028 revenue of $6.31bn; the disagreement is the margin the book earns and the multiple a two-thirds-leased book deserves. Street: Buy, 17-analyst consensus target $78.19.

- THE OPERATING LEVERAGE WENT BACKWARDS: revenue rose $206M in FY2026 while Adjusted EBITDA FELL $24M, an incremental margin of MINUS 11.7%. Margin 53.8% to 34.8% for the year, and 41.1% to 14.0% in the June quarter. SG&A tripled, $136.5M to $449.1M. Stock-based compensation of $205.0M is 83% of the entire $245.7M of Adjusted EBITDA and is added back to reach it.

- THE CAPEX DENOMINATOR: every reassurance is scoped to GPU capex only. Footnote 3 defines the roughly two-year payback as GPU capital expenditure divided by contracted revenue less direct costs. But the FY2026 cash flow shows $2,998.0M of property, plant and equipment NET of computer hardware against $1,335.1M of computer hardware - $2.25 of site for every $1.00 of compute. The financings fund the smaller half.

What to watch: UP: the first quarter that recognises real lease revenue at a margin near the 86.9% AI Cloud gross line. Horizon 1 was delivered to and accepted by Microsoft in August 2026, so fiscal Q1 2027 is the first clean read on what a delivered hall actually earns. DOWN: another quarter of Adjusted EBITDA margin near the 14.0% posted in the June quarter, or more equity sold ahead of signed contracts.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Titan Machinery (TITN) Q2 FY2027 — Q2 FY2027 (quarter ended 31 July 2026): revenue $496.4M, down 9.2%, ahead of a $483.8M consensus; diluted loss per share $0.40 against a three-analyst bar of $0.36. Gross margin 18.6%, up 148bps. Adjusted EBITDA $4.6M from $5.6M. Inventory down 18.3% year on year to $931.5M; floorplan payable down 26.8% to $623.6M; floorplan interest halved to $3.7M. FY2027 profitability guidance reaffirmed at an adjusted loss of $1.25-$1.75. The stock fell 2.07% to $18.42.

Titan spent two years promising to clear excess machines off its lots, and it delivered: inventory fell 18.3% year on year against a 9.2% revenue decline, floorplan debt fell 26.8% and floorplan interest was cut in half. The pre-tax loss got wider anyway, $9.2M against $8.2M. The reason is dealer absorption - recurring parts, service and rental gross profit as a share of operating expenses - which fell 578bps to 68.5%, a four-year low, in the very quarter equipment margin recovered.

THE CALL: HOLD (3/5, THE BALANCE SHEET HEALED, THE INCOME STATEMENT DID NOT) — base-case value ~$17.0 vs ~$18.42 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$17.00 vs the $18.42 reaction close (-7.7%). Bear $9.12, base $17.77, bull $23.78. Street: Buy, $23.00 consensus (Northland $25, Baird $17) - but no analyst has published since 15 June 2026.

- THE DESTOCK IS REAL: inventory $1.14bn to $931.5M (-18.3%) against revenue -9.2%, so stock cleared roughly twice as fast as sales fell. Floorplan payable $852.2M to $623.6M. Floorplan interest $6.8M to $3.7M. Equipment gross margin 6.61% to 8.52%, up 192bps.

- ABSORPTION IS THE PROBLEM: recurring gross profit $68.8M to $64.4M (-6.4%) while operating expense rose 1.5% on 9.2% less revenue. Absorption 76.7% / 72.9% / 74.2% / 68.5% across four fiscal Q2s. One point is worth ~$3.8M pre-tax, ~12c of EPS.

What to watch: UP: recurring gross profit growing year on year with operating expense flat, in both the October and January quarters - roughly $0.70 a share of earnings power; a fiscal Q3 that clears last year's $0.05; equipment margin holding above 11.3%. DOWN: a third consecutive year of operating expense rising in dollars on falling revenue; Europe deteriorating past the new down 30-40% outlook; absorption printing below 68%.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Malibu Boats (MBUU) Q4 FY2026 — Q4 FY2026 (quarter ended 30 June 2026): net sales $295.5M, up 42.7%; adjusted EPS $0.92 vs a $0.779 consensus; adjusted EBITDA $33.9M, up 72.7%. GAAP diluted EPS was $0.37. Full-year net sales $914.6M, up 13.3%, but FY26 gross margin fell 180bps to 16.0%, adjusted EBITDA fell 1.1% and GAAP EPS fell to $0.09 from $0.76. FY2027 guidance: net sales $1.08-1.12bn, adjusted EBITDA $101-109M. The stock rose 8.11% to $28.80.

Malibu bought Finnish builder Saxdor on 2 March 2026, so fiscal 2026 contains four months of it, not twelve. Measured against reported net sales of $914.6M, FY27 guidance looks like 18-22% growth. At 7:45am the NEXT morning Malibu filed an item 8.01 pro forma showing FY2026 net sales of $1,050.9M with Saxdor owned all year - against which the same guide is 2.8-6.6%, and the pro forma bottom line is a LOSS of $0.11 a share.

THE CALL: HOLD (3/5, A GOOD QUARTER, EXTRAPOLATED TOO FAR) — base-case value ~$27.0 vs ~$28.8 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$27.00 vs the $28.80 reaction close (-6%). Bear $22.16, base $27.85, bull $30.70 at 7.0x EV/EBITDA. Street: Hold, consensus target $32.00 (Truist $34, B. Riley $30).

- THE BEAT WAS REAL: Q4 adjusted EPS $0.92 vs $0.779, on adjusted basis (the four FY26 quarters sum to $1.61 vs a filed full-year adjusted $1.52; full-year GAAP was $0.09). But $61.2M of the $88.5M revenue increase and 180 of the 235 extra units were Saxdor.

- THE FULL YEAR WENT BACKWARDS: legacy unit volume -4.1%, gross margin 17.8% to 16.0%, adjusted EBITDA -1.1%, GAAP net income -88.8%. Net debt $90.6M from net cash. FY26 revenue beat the company's own May guide by ~$29M and produced ~$1M of extra EBITDA.

What to watch: UP: two consecutive quarters of gross margin at or above 17.5% with legacy unit volume no longer falling; Saxdor production starting on schedule at Fort Pierce, Florida. DOWN: a second write-down of the Saxdor earnout, already marked from $32.6M to $29.9M; gross margin stalling near 16%; dealer inventories falling faster than guided.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Harmony Gold (HMY) FY2026 — FY2026 (twelve months ended 30 June 2026): revenue R99,238M (US$5,876M), up 34%. Headline EPS 4,363 SA cents (258 US cents), up 87%. Basic EPS 4,701 SA cents, up 103% - the gap is a R2,779M non-cash impairment reversal. Record adjusted free cash flow US$1,015M. Gold produced 1,429,551oz, DOWN 3%, at an AISC of US$2,195/oz, UP 22% in dollars. First copper: 18,207t from CSA. Net debt R852M, from net CASH of R11,148M, after the US$1.0bn MAC Copper deal. Final dividend 750 SA cents vs 155. FY27 guides 1.30-1.40Moz - below FY26 actual - on roughly US$1.70bn of capex. The 6-K was accepted 27 August pre-open; the ADR closed -6.24% at $21.03 on 7,885,729 shares, then $20.04 on 28 August.

Harmony reported the best year in its history and the ADR fell 6.24% on 2.9x median volume, with gold at a record. Here is what the tape worked out. FIRST: the earnings were already public. JSE rules forced a trading statement on 21 August, six days early, and the ADR rose 6.9% that day; the actual print landed INSIDE the pre-announced range. SECOND: revenue is stated AFTER a realised gold hedge loss of R9,649M (US$571M), more than double last year and MORE than the entire record dividend of US$503M. THIRD: 618,000oz of FY27 output is already collared at an average ceiling of R2,403,903/kg, and spot rand gold sits just 2.6% below it. FOURTH: FY27 asks for LESS gold at a HIGHER cost, on roughly US$1.70bn of capex against US$934M of actual FY26 free cash flow, with the net cash already spent.

THE CALL: HOLD (3/5, A RECORD YEAR THAT WAS PUBLISHED TWICE, HEDGED HEAVILY, AND ALREADY SPENT) — base-case value ~$18.6 vs ~$20.04 today.

KEY METRICS:

- CALL: HOLD 3/5, fair value ~$18.60 vs the $20.04 Aug 28 close (-7%). Bear $10.61, base $19.74, bull $24.96. Street: Hold, 10 analysts, avg target $20.97.

- HEPS 258 US cents, +87%. Revenue US$5,876M, +34%. But revenue is NET of a US$571M realised gold hedge loss - more than the US$503M record dividend.

- FY27 guides LESS gold (1.30-1.40Moz vs 1,429,551) at HIGHER cost, on ~US$1.70bn capex vs US$934M FY26 free cash. 7.8x HEPS, 5.0x EBITDA, 3.9% yield.

What to watch: UP: the December half-year showing collared ounces below 400,000, or ceilings rolled up toward the R2,805,213 struck in Q4; gold sustained above $4,750; the rand weakening toward R17.50, which cuts dollar AISC; Eva Copper's environmental approval landing on schedule. DOWN: gold below $4,250, which takes FY27 free cash flow to about US$605M against US$1.70bn of committed capital; the rand through R16.00, inflating dollar costs; grade slipping below the guided 5.60g/t after three years of decline; a further Eva permitting delay; any additional restatement after FY25 was restated.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Phibro Animal Health (PAHC) Q4 FY2026 — FY2026 (year ended June 30, 2026): net sales $1,518.1m vs $1,296.2m, up 17.1%; adjusted EBITDA $255.0m vs $183.7m, up 38.8%; adjusted diluted EPS $3.22 vs $2.17; GAAP diluted EPS $2.43. Q4 adjusted EPS $0.85 against a $0.71 bar, a 19% beat, on sales of $396.7m. Free cash flow $9.9m. The stock opened +9.1% at $39.39 on August 27, traded to $35.01 and closed $36.35, up 0.72% on 432,907 shares, 2.4x its 30-session median.

Phibro filed its 10-K at 16:14 Eastern on August 26 and the results 8-K at 16:30, both just after the close, and the stock opened up 9.1% the next morning before closing up 0.72%. Nearly the whole gap was given back in one session. The record is real: net sales $1,518.1m, adjusted EBITDA $255.0m up 38.8%, adjusted EPS $3.22 against a $0.71 fourth-quarter bar it beat by 19%, and FY2027 guidance that came in 5.4% ABOVE the published consensus rather than below it. But $146.1m of the $221.9m sales increase is the company's own disclosed incremental revenue from the Zoetis MFA portfolio, which closed October 31, 2024 - four extra months on a calendar. And $255.0m of adjusted EBITDA produced $9.9m of free cash flow.

THE CALL: HOLD (3/5, A REAL BEAT AND A REAL RECORD YEAR THAT CONVERTED ALMOST NONE OF ITSELF INTO CASH) — base-case value ~$37.03 vs ~$36.35 today.

KEY METRICS:

- THE SPINE: $255.0m of adjusted EBITDA produced $9.9m of free cash flow - 3.9% conversion, against 22.8% the year before.

- SAME TWELVE MONTHS: adjusted EBITDA rose $71.3m while operating cash flow FELL $11.2m, from $80.1m to $69.0m.

- WHERE IT WENT: working capital absorbed $95.1m, $86.3m of it inventory. Capex rose 54% to $59.1m against $51.5m of D&A.

- THE GROWTH: $146.1m of the $221.9m sales increase is disclosed incremental Zoetis MFA revenue - four extra months of a deal that closed Oct 31, 2024.

- ONCE LAPPED: in Q4, with both years carrying a full acquisition, MFAs grew $1.1m on $206.5m. Mineral Nutrition was 71% of the quarterly increase.

- THE CONCESSION: the beat is real on the proven adjusted basis, guidance came in 5.4% above consensus, and Animal Health margin expanded 303bp.

- THE GUIDE: FY2027 adjusted EBITDA +3.1%, but adjusted EPS +8.7% - and 58% of that earnings growth is the tax rate going 23.7% to about 20%.

- OUR CALL: HOLD, 3/5, fair value $37.03 vs $36.35. Bear $27.81, base $38.90, bull $48.19. Street average $45.00 across five analysts.

What to watch: UP: the Q4 beat is real on the proven basis - $0.85 against $0.713, with sales 4.1% ahead; FY2027 adjusted EPS guidance of $3.41-$3.59 is 5.4% above the $3.32 consensus; Animal Health adjusted EBITDA margin expanded 303bp to 26.1%; Brazil virginiamycin, about $27m of FY2026 sales, is already assumed at near zero in guidance, so registration is unbooked upside; Phibro Forward closed June 30 and management traces nearly one in five guided EBITDA dollars to it; gross leverage 2.9x and no large maturity until $406.6m in FY2030. DOWN: free cash flow $9.9m against $255.0m of adjusted EBITDA, a 3.9% conversion versus 22.8%; operating cash flow FELL $11.2m to $69.0m while adjusted EBITDA rose $71.3m; working capital took $95.1m, of which inventory was $86.3m; inventory $534.9m is 194 days of COGS against 181; capex +54% to $59.1m; the dividend cost $19.5m, twice free cash flow; guidance is +3.1% EBITDA growth and assumes zero FX losses after $12.6m.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Build-A-Bear Workshop, Inc. (BBW) Q2 FY2026 — Q2 FY2026 (thirteen weeks ended August 1, 2026): revenue $115.291m vs $124.247m, -7.2%; e-commerce demand -15.6%; gross margin 54.2% vs 57.6%; pre-tax income $11.631m vs $15.318m; diluted EPS $0.70 vs $0.94 against a $0.645 bar, so it BEAT. The shares gapped -14.99% and closed $28.44, -27.26%, on 14.8x the twelve-month median volume.

Build-A-Bear Workshop BEAT its earnings bar - $0.70 against $0.645 - and fell 27.26%, its worst session in a year. What was repriced was not the quarter, it was the plan: in May commercial (wholesale) revenue was guided to grow at least 20% this year, and on August 27 it was guided flat, the Chief Growth Officer was terminated in the same 8-K, and the full-year outlook was cut for the second time in three months.

THE CALL: HOLD (3/5, A DEBT-FREE BRAND ON EIGHT TIMES ITS OWN GUIDANCE, WITH ITS GROWTH LEG GUIDED TO ZERO) — base-case value ~$32.30 vs ~$28.44 today.

KEY METRICS:

- THE STREET AND THE CALL: NOT ONE sell-side target was struck after this print. Two could be sourced AND dated - D.A. Davidson Buy $60 (May 29, 2026) and Northland Outperform $80 (Aug 29, 2025). We value BBW at $32.30 vs $28.44 on three methods spanning 1.08x: DCF $30.76, owner earnings $32.95, EV/EBITDA $33.21. HOLD, 3/5. Bull $44.78, bear $21.71.

- THE SPINE: revenue fell $8.956m and cost of merchandise sold ROSE $0.066m, because store occupancy is reported INSIDE that line. Gross profit fell $9.022m - 100.7% of the entire sales decline landed in profit. Gross margin 57.6% to 54.2%, while SG&A actually LEVERAGED 80bp.

- THE GROWTH LEG INVERTED IN ONE QUARTER: commercial (wholesale) revenue was +43.6% in Q1 ($7.622m to $10.948m) and -6.3% in Q2 ($8.629m to $8.086m). The CEO: 'certain wholesale opportunities may take longer to realize than previously anticipated.'

- SO THE GUIDE REMOVED IT: 'commercial revenue growth of AT LEAST 20%' in May became 'approximately flat' in August - $7.75m out of the plan on last year's $38.750m, and an implied second half 12.4% BELOW last year's.

- AND THE CHIEF GROWTH OFFICER WENT WITH IT, IN THE SAME 8-K. Item 5.02: David Henderson terminated WITHOUT CAUSE on August 26, the day before the print. The role was created June 11, 2026 - 76 days earlier - at the CEO handover. Severance $501,500. We label the link an inference, not a proof.

- THE YEAR HAS BEEN CUT TWICE IN THREE MONTHS: revenue mid-single-digit GROWTH in March, $530m-$550m in May, $500m-$525m now; adjusted pre-tax $65m-$71m became $53m-$61m. The TOP of the new revenue range, $525m, sits BELOW fiscal 2025's $529.832m: the five-year record streak ends.

- READ THE 'BACK-HALF WEIGHTED' YEAR AS ARITHMETIC: H1 adjusted pre-tax was $28.5m, so the guide implies $24.5m-$32.5m for H2 against $32.3m last year. The TOP of the range merely MATCHES last year - and still contains about $6m of IEEPA tariff refund.

What to watch: UP: it beat the bar; no borrowings; 8.2x its own adjusted guidance and a 3.23% dividend; 44% of the 674-location fleet is partner-operated or franchised. DOWN: revenue -7.2% while cost of merchandise sold ROSE, so 100.7% of the sales decline landed in profit; the revenue guide now tops out BELOW fiscal 2025's record; cash -64% to $14.0m.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Standard Nuclear (STDN) Q2 2026 — Q2 2026 (three months ended June 30, 2026): total revenue $4.74m vs $0.55m, up 756%; product revenue $3.10m from the first commercial TRISO delivery; gross profit $3.18m, a 67.2% margin and the first ever; G&A $5.52m, R&D $1.96m; operating loss $4.30m; net loss $3.42m, $(0.12) per share on 28.0m pre-IPO shares. The stock closed $14.31 on August 27, up 4.45% on 796,970 shares.

Standard Nuclear filed its results in an Item 2.02 8-K at 20:26 Eastern on August 26 - an exhibit EDGAR's own index does not list - with the 10-Q following at 08:09 the next morning. The stock opened just 1.0% higher, traded below its prior close, and finished at $14.31, its high of the day and its best close since the July 16 listing. The quarter is the first with a product in it: 50 kgU of TRISO delivered to Radiant for $3.10m, the first complete reactor core of commercially produced TRISO from an independent US maker. It is also the first time this backlog has a price per kilogram behind it.

THE CALL: BEARISH (3/5, A REAL FIRST DELIVERY AND A PRICE THAT ALREADY NEEDS MORE PLANTS THAN HAVE BEEN ANNOUNCED) — base-case value ~$8.64 vs ~$14.31 today.

KEY METRICS:

- THE SPINE: the first delivery prices TRISO. 50 kgU for $3.10m is $62,000/kgU - the first observable price this company has printed.

- CROSS-CHECK: the Antares firm one-ton commitment lifted Funded Backlog 93% to $119.3m. That $57.4m for one MTU is $57,400/kgU.

- THIRD ROUTE: the seven-ton option added $287.0m to Purchase Options, or $41,000/kgU. Three routes, spanning just 1.51x.

- THE CEILING: every announced plant fully ramped is 6.83 MTU a year, or $392m of revenue. The enterprise value is $2.00bn - 5.1x that.

- THE REVERSE TEST: at 12% over 5 years to a 20x terminal on a 25% margin, $2.00bn needs $705m of revenue - 12.3 MTU, 1.8x the whole plan.

- THE CAVEAT: only 21% of the $576.9m backlog binds. The release itself says it is not a measure of contracted revenue.

- THE CONCESSION: first ever gross profit $3.18m at 67.2%, backlog up six-fold since March, $239.9m of cash and no debt at all.

- OUR CALL: BEARISH, 3/5, fair value $8.64 vs $14.31. Bear $2.38, base $8.16, bull $15.88. Six targets, all dated August 10, average $15.50.

What to watch: UP: revenue $4.74m from $0.55m; first gross profit $3.18m at 67.2%; Total Contract Backlog $91.3m to $576.9m since March; Funded Backlog $8.2m to $119.3m; $239.9m pro forma cash, no debt, total liabilities $9.5m; construction substantially complete at both new plants; DOE approved the preliminary safety analysis for each. DOWN: the six-month column still shows a $1.23m gross LOSS; only 21% of the headline backlog binds and 77% is unexercised options; free cash outflow $28.4m in six months; neither new plant is authorised to operate; two customers were 89% of the quarter; the stock has never closed above its $15.00 IPO price.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Mesoblast (MESO) FY2026 — FY2026 (twelve months ended June 30, 2026): total revenue $120.25m vs $17.2m, up 599.2%; net Ryoncil product sales $115.2m vs $11.3m; gross profit ex-amortisation $109.7m, a 91.2% margin; R&D $97.5m vs $34.8m; SG&A $57.3m vs $39.3m; reported loss $57.5m vs $102.1m; loss per ADS $0.444. The ADS closed $18.18 on August 27, up 7.96% on 541,633 shares, 3.0x its 30-session median.

Mesoblast filed its audited 20-F at 06:08 Eastern on August 27 and the results 6-K at 07:09, both before the open, and the stock closed up 7.96% on three times median volume. The launch is real: Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, did $115.2m of net product sales in its first full year, the second half out-earned the first by 34.2%, and the fourth quarter alone did $36m. The release leads with a loss cut 44% to $57.5m. But $32.8m of that $44.6m improvement - 73.4% - is the swing in two non-cash fair value lines. Strip them and $103.1m of new revenue bought $11.9m of loss reduction.

THE CALL: BEARISH (3/5, A GENUINELY GOOD FIRST LAUNCH YEAR THAT IS NOT WHAT THE SHARE PRICE IS PAYING FOR) — base-case value ~$14.28 vs ~$18.18 today.

KEY METRICS:

- THE SPINE: the reported loss narrowed $44.6m, but $32.8m of that - 73.4% - is two non-cash fair value marks, not the business.

- EX-MARKS: the underlying loss went $82.3m to $70.4m. So $103.1m of new revenue bought $11.9m of improvement - 11.5% drop-through.

- THE MARKS: contingent consideration swung from a $14.9m charge to a $12.1m gain; the warrant liability from a $5.0m charge to a gain.

- THE CASH: $88.4m received against $120.25m booked. Receivables $14.9m to $57.7m, 175 days, and one customer is the entire product book.

- THE BALANCE SHEET: intangibles $566.4m are 99.6% of $568.4m net assets. Borrowings $119.2m vs $102.9m cash - net debt, in year one.

- THE CONCESSION: second-half revenue $68.9m vs $51.3m, +34.2%. Q4 product sales $36m annualise to $144m. 50 centres, 280m covered lives.

- WHAT YOU PAY FOR: our approved franchise is $9.87 an ADS. The tape is $18.18, so $8.31 - 46% - is six unapproved programmes.

- OUR CALL: BEARISH, 3/5, fair value $14.28 vs $18.18. Bear $7.28, base $14.16, bull $21.51. Two April targets, both $35.00.

What to watch: UP: revenue $120.25m beat the $117.5m seven-analyst consensus by 2.3%; second-half revenue $68.9m against a $51.3m first half; Q4 product sales $36m annualise to $144m; operating cash outflow only $13.4m in the second half; gross-to-net 13.4% against 14.6%; 50+ transplant centres including 14 of the 15 largest; 280m covered lives; time to treatment 29 days to 8. DOWN: cash receipts $88.4m against $120.25m of revenue; receivables $14.9m to $57.7m, 175 days, and the 20-F says one single external customer is the whole product book; intangibles $566.4m are 99.6% of net assets; borrowings $119.2m against $102.9m of cash is net debt; finance costs $23.8m are 19.8% of revenue.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.